title: Safety of influenza immunizations and treatment during pregnancy: the Vaccines and Medications in Pregnancy Surveillance System.
abstract: The Vaccines and Medications in Pregnancy Surveillance System (VAMPSS) has been designed to assess systematically the safety of vaccines and medications during pregnancy and is suited ideally to evaluate the gestational safety of seasonal and pandemic influenza vaccine and influenza antivirals. VAMPSS is coordinated by the American Academy of Allergy Asthma and Immunology and includes 2 complimentary data collection arms (prospective cohort and case-control surveillance) and a standing independent advisory committee. Both data collection arms obtain information directly from the mother, which facilitates accurate capture of exposures and potential confounders. The full range of perinatal outcomes, which includes specific birth defects, is assessed. Information that is obtained from VAMPSS should allow enhanced prevention and improved treatment of influenza during pregnancy by the identification of any exposures that might be associated with important risks and the provision of reassurance for exposures that are found to be relatively safe.
authors.affiliation: American Academy of Allergy Asthma and Immunology, Milwaukee, WI, USA. michael.x.schatz@kp.org
authors.forename: Michael
authors.initials: M
authors.lastname: Schatz
authors.forename: Christina D
authors.initials: CD
authors.lastname: Chambers
authors.forename: Kenneth Lyons
authors.initials: KL
authors.lastname: Jones
authors.forename: Carol
authors.initials: C
authors.lastname: Louik
authors.forename: Allen A
authors.initials: AA
authors.lastname: Mitchell
mesh_terms: D016907:Adverse Drug Reaction Reporting Systems; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use; D016022:Case-Control Studies; D000013:Congenital Abnormalities; D005260:Female; D006801:Humans; D007114:Immunization / Q000009:adverse effects; D053118:Influenza A Virus, H1N1 Subtype / Q000276:immunology*; D007252:Influenza Vaccines / Q000009:adverse effects; D007251:Influenza, Human / Q000188:drug therapy / Q000517:prevention & control; D053139:Oseltamivir / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy / Q000517:prevention & control; D011297:Prenatal Exposure Delayed Effects; D011446:Prospective Studies; D018570:Risk Assessment; D012955:Societies, Medical; D014481:United States; D053243:Zanamivir / Q000009:adverse effects / Q000627:therapeutic use
chemical_list: D000998:Antiviral Agents; D007252:Influenza Vaccines; D053139:Oseltamivir; D053243:Zanamivir